CHALLENGE 05
Treating Security, Governance, and Risk as Late-Stage Checkboxes
A Health IT company can generate strong clinical or operational interest and still lose momentum when the provider begins evaluating security, governance, privacy, integration, or organizational risk.
That is because hospitals and health systems are not simply deciding whether the technology works.
They are deciding whether they can trust the technology, the vendor, and the organization behind it enough to introduce the solution into a complex healthcare environment.
Too many companies treat security review, AI governance, risk assessment, and technical diligence as hurdles that appear after the “real” selling has been completed.
For the provider, they are part of the buying decision.
In Health IT, trust is not something you add to the sales process. Trust is part of what you are selling.
Seller’s Lens vs. Buyer’s Lens
Health IT companies often see security, governance, and risk review as technical approval steps that follow business interest. Providers see them as evidence of whether the organization can safely and responsibly adopt the solution.
Seller’s Lens
“We can handle security review when we get there.”
The seller sees:
- strong product performance;
- enthusiastic clinical or operational users;
- demonstrated value;
- technical capabilities;
- security questionnaires;
- compliance documentation;
- contracting requirements;
- and an approval process that comes later in the deal.
From the seller’s perspective, security and governance are requirements to clear once the buyer wants the product.
Buyer’s Lens
“Can we trust this solution and this company enough to bring them into our environment?”
The provider is asking:
- What data will the solution access?
- How is sensitive information protected?
- What happens when something fails?
- How mature is the vendor’s security program?
- Who owns security and risk inside the company?
- How is AI monitored after deployment?
- What changes require provider notification?
- How transparent will the vendor be when problems occur?
The provider is not only evaluating product risk. It is evaluating vendor risk.
Why This Becomes a GTM Problem
When security, governance, and risk are deferred until late in the sales process, the vendor may discover that business enthusiasm has advanced much faster than organizational readiness.
Operational Approval Creates False Confidence
The business team says yes, and the seller assumes the hard part is over—just as security and governance review begins.
The Questionnaire Becomes a Fire Drill
Documentation is assembled reactively because the company has not prepared for provider diligence.
Security Ownership Is Unclear
The provider cannot identify who inside the vendor organization is accountable for cybersecurity and risk.
AI Governance Appears Late
Questions about model use, monitoring, data, human oversight, and material changes surface after the product discussion is well underway.
The Vendor Overstates Readiness
Answers are optimized to get through review rather than clearly acknowledging gaps, mitigation plans, and residual risk.
Surprises Reach Contracting
Issues that could have been addressed earlier become expensive legal, technical, or commercial problems late in the deal.
Security review does not interrupt the sale. It is part of the sale.
Provider Perspective
Gary S. Chan
Chief Information Security Officer, SSM Health
Yasir Tarabichi, MD, MSCR
Chief Health AI Officer, MetroHealth / Head of Digital & CMIO, Ovatient
Sam Morhaim
Co-founder & Chief Innovation/Technology Officer, VantageIO
Ram D. Sriram
Senior Science Advisor, Information Technology Laboratory,
National Institute of Standards and Technology
Gary S. Chan
Chief Information Security Officer, SSM Health
Security Readiness Builds Trust
Provider security teams are not simply checking boxes.
They are trying to understand the risk the technology and vendor introduce into the organization, including how seriously the company takes security internally.
Preparation matters.
A vendor that already understands common healthcare security requirements, maintains appropriate documentation, has accountable security leadership, and responds transparently creates a very different impression from one discovering those expectations for the first time during a live opportunity.
The GTM implication
Prepare for provider security diligence before the first security questionnaire arrives.
Yasir Tarabichi, MD, MSCR
Chief Health AI Officer, MetroHealth / Head of Digital & CMIO, Ovatient
AI Governance Does Not End at Approval
AI introduces questions that extend beyond traditional technology review.
Providers need to understand how the technology is governed, monitored, changed, and managed after deployment—not merely how the model performed during evaluation.
That makes governance an ongoing operational responsibility rather than a one-time approval event.
The GTM implication
If the solution includes AI, be prepared to explain how it will be governed after it enters the provider environment.
Sam Morhaim
Founder and CEO, Vantage IO
Hospital-Ready Is Different From Demo-Ready
An impressive AI demonstration does not automatically mean the technology is ready to operate inside a health system.
Providers must consider integration, technical architecture, workflow, reliability, risk, and what happens when the product encounters real-world conditions that were not visible in the demo.
The GTM implication
Do not confuse technical capability with organizational readiness.
Ram D. Sriram
Chief of the Software and Systems Division
National Institute of Standards and Technology
Trustworthy AI Requires Evidence
AI confidence depends on more than model performance.
Providers and other decision-makers increasingly need evidence around uncertainty, measurement, monitoring, and how the system behaves when predictions are incomplete or wrong.
That means vendors need to communicate not only what the model can do, but how its performance and limitations are understood.
The GTM implication
Trust increases when the vendor can explain both the capability of the technology and the boundaries of that capability.
How to Diagnose Security, Governance & Risk Readiness
Prepare Before the Review Begins
Do not wait for a live deal to discover what healthcare organizations will ask.
A provider may expect evidence such as:
- documented security policies;
- independent assessments;
- penetration testing;
- SOC 2 reports or other relevant security attestations or certifications;
- privacy practices;
- incident-response procedures;
- data-flow documentation;
- business-continuity plans;
- and clearly identified security ownership.
Not every vendor will have every certification or control.
The important issue is whether the company understands its current maturity, can document it honestly, and has a plan for known gaps.
Security readiness should be built before the sales process exposes the gaps.
Treat Vendor Security Culture as Part of the Product
Providers are evaluating more than the application.
They are evaluating the company behind it.
That includes:
- whether security has dedicated ownership;
- whether employees understand their responsibilities;
- whether risk is discussed proactively;
- whether independent validation is used;
- how incidents are handled;
- and whether the company communicates openly when problems arise.
A technically strong product supported by an immature vendor security program may still represent unacceptable risk.
The provider is buying your organization’s security maturity along with your technology.
Make Governance and Monitoring Explicit
This becomes especially important with AI.
The provider may need to understand:
- who governs the technology;
- how performance is monitored;
- what happens when performance changes;
- how users report problems;
- how model or product changes are communicated;
- what human oversight remains;
- what data is used;
- and who is accountable when something goes wrong.
Those questions should not surprise the commercial team.
Approval answers whether the solution can enter the organization. Governance answers how it will remain there responsibly.
Be Clear About Risk, Limitations, and Failure Modes
Trust does not require pretending that risk does not exist.
Every technology has limitations.
A more credible conversation explains:
- what could go wrong;
- how likely it is;
- how the problem would be detected;
- what controls reduce the risk;
- what the provider needs to do;
- and what happens when the technology does not perform as expected.
For AI, that may include uncertainty, incomplete data, model error, workflow failure, or changing performance over time.
A provider can work with known risk. Unexpected risk discovered late is much harder to manage.
Diagnostic Content — Bottom Line
Security and governance readiness means giving the provider confidence that the technology, the vendor, and the risks surrounding both can be understood, managed, monitored, and trusted.
Better Discovery Questions — Don’t Ask / Ask Instead
Good risk discovery does not try to determine how quickly the vendor can get through security review. It helps the vendor understand what the provider must know before it can confidently approve the solution.
DON’T ASK
“How long does your security review usually take?”
ASK INSTEAD
“What security and risk requirements should we understand early so we can prepare the right evidence before formal review begins?”
DON'T ASK
“Do you require SOC 2?”
ASK INSTEAD
“What evidence does your organization rely on to assess the security maturity of a technology vendor?”
DON'T ASK
“Once security approves us, are we done?”
ASK INSTEAD
“What ongoing governance, monitoring, reporting, or change-notification requirements will remain after deployment?”
The objective is not simply to pass the review. It is to understand what the provider needs in order to trust the solution and the vendor behind it.
From Product Interest to Organizational Trust
Before treating strong business interest as evidence of commercial readiness, the sales team should understand the security, governance, and risk requirements that could determine whether the provider can actually adopt the solution. The Buyer’s-Lens Test helps distinguish product enthusiasm from organizational trust.
1. Questions Health IT Companies Should Be Able to Answer
☐ What provider data will the solution access?
☐ What security controls protect that data?
☐ Who owns cybersecurity and risk internally?
☐ What independent security evidence is available?
☐ What known gaps or limitations exist?
☐ How are incidents identified and managed?
☐ What governance requirements apply after deployment?
☐ How is product or AI performance monitored?
☐ How are material changes communicated?
☐ What happens when the technology behaves unexpectedly?
☐ What responsibilities remain with the provider?
☐ Can the company clearly explain its risk-mitigation plan?
If the sales team cannot explain how the provider’s risk will be managed, the opportunity is not yet commercially ready—regardless of how much the business users like the product.
The Buyer’s-Lens Test
A security- and governance-ready opportunity should allow the provider to answer “yes” to each of the following:
✓ Yes, we understand the risk.
The organization knows what the technology and vendor introduce into the environment.
✓ Yes, the vendor demonstrates security maturity.
There is evidence of ownership, controls, documentation, and responsible security practices.
✓ Yes, the limitations are transparent.
The vendor can explain what the technology cannot guarantee and how risk is mitigated.
✓ Yes, ongoing governance is defined.
Monitoring, reporting, accountability, and change management continue after approval.
✓ Yes, we trust the vendor to tell us when something changes.
The relationship is built on transparency rather than surprises.
When those five answers are present, security and governance stop being obstacles to clear and become evidence that the provider can trust the solution enough to move forward.
David's GTM Takeaway
Health IT companies sometimes treat security, governance, and risk as obstacles that appear late in the buying process.
Providers cannot afford to.
They are introducing technology into environments where patient care, sensitive information, operational continuity, reputation, and regulatory responsibilities may all be affected.
The commercial team therefore needs to understand these requirements before they become late-stage surprises.
Prepare the evidence.
Know the gaps.
Understand the risks.
Be transparent about what the technology can—and cannot—do.
In Health IT, trust is not something you add to the sales process. Trust is part of what you are selling.